Benjamin Z Leder1. 1. Harvard Medical School, Endocrine Unit, Massachusetts General Hospital, Boston, USA. bzleder@partners.org.
Abstract
PURPOSE OF REVIEW: The purpose is to review the efficacy and optimal use of parathyroid hormone and parathyroid hormone-related protein analogs in osteoporosis treatment. RECENT FINDINGS: The parathyroid hormone analog teriparatide, a potent stimulator of bone remodeling, increases hip and spine bone mineral density and reduces the risk of vertebral and non-vertebral fractures in postmenopausal osteoporotic women. The parathyroid hormone-related protein analog, abaloparatide, also reduces fracture incidence but has pharmacological effects that differ from teriparatide, particularly in cortical bone. These analogs provide maximal benefit when their use is followed by a potent antiresorptive medication. Moreover, studies have shown that the combination of teriparatide and the RANK-ligand inhibitor, denosumab, increase bone density and estimated strength more than monotherapy and more than any currently available regimen. Parathyroid hormone and parathyroid hormone-related protein analogs, whether as monotherapy, in combination with antiresorptive agents or in sequence with antiresorptive agents, will likely play an expanding role in osteoporosis management.
PURPOSE OF REVIEW: The purpose is to review the efficacy and optimal use of parathyroid hormone and parathyroid hormone-related protein analogs in osteoporosis treatment. RECENT FINDINGS: The parathyroid hormone analog teriparatide, a potent stimulator of bone remodeling, increases hip and spine bone mineral density and reduces the risk of vertebral and non-vertebral fractures in postmenopausal osteoporoticwomen. The parathyroid hormone-related protein analog, abaloparatide, also reduces fracture incidence but has pharmacological effects that differ from teriparatide, particularly in cortical bone. These analogs provide maximal benefit when their use is followed by a potent antiresorptive medication. Moreover, studies have shown that the combination of teriparatide and the RANK-ligand inhibitor, denosumab, increase bone density and estimated strength more than monotherapy and more than any currently available regimen. Parathyroid hormone and parathyroid hormone-related protein analogs, whether as monotherapy, in combination with antiresorptive agents or in sequence with antiresorptive agents, will likely play an expanding role in osteoporosis management.
Entities:
Keywords:
Abaloparatide; Anabolic agents; Bone mineral density; Combination therapy; Osteoporosis; Parathyroid hormone; Teriparatide
Authors: R S Rittmaster; M Bolognese; M P Ettinger; D A Hanley; A B Hodsman; D L Kendler; C J Rosen Journal: J Clin Endocrinol Metab Date: 2000-06 Impact factor: 5.958
Authors: D W Dempster; F Cosman; E S Kurland; H Zhou; J Nieves; L Woelfert; E Shane; K Plavetić; R Müller; J Bilezikian; R Lindsay Journal: J Bone Miner Res Date: 2001-10 Impact factor: 6.741
Authors: R M Neer; C D Arnaud; J R Zanchetta; R Prince; G A Gaich; J Y Reginster; A B Hodsman; E F Eriksen; S Ish-Shalom; H K Genant; O Wang; B H Mitlak Journal: N Engl J Med Date: 2001-05-10 Impact factor: 91.245
Authors: John L Vahle; Masahiko Sato; Gerald G Long; Jamie K Young; Paul C Francis; Jeffery A Engelhardt; Michael S Westmore; Yanfei Linda; James B Nold Journal: Toxicol Pathol Date: 2002 May-Jun Impact factor: 1.902
Authors: E S Orwoll; W H Scheele; S Paul; S Adami; U Syversen; A Diez-Perez; J M Kaufman; A D Clancy; G A Gaich Journal: J Bone Miner Res Date: 2003-01 Impact factor: 6.741
Authors: Jean-Jacques Body; Gregory A Gaich; Wim H Scheele; Pandurang M Kulkarni; Paul D Miller; Anne Peretz; Robin K Dore; Ricardo Correa-Rotter; Alexandra Papaioannou; David C Cumming; Anthony B Hodsman Journal: J Clin Endocrinol Metab Date: 2002-10 Impact factor: 5.958
Authors: Joshua N Farr; Megan M Weivoda; Kristy M Nicks; Daniel G Fraser; Brittany A Negley; Jennifer L Onken; Brianne S Thicke; Ming Ruan; Hong Liu; Douglas Forrest; John R Hawse; Sundeep Khosla; David G Monroe Journal: J Bone Miner Res Date: 2017-12-27 Impact factor: 6.741
Authors: Yu Shao; Emily Wichern; Paul J Childress; Michele Adaway; Jagannath Misra; Angela Klunk; David B Burr; Ronald C Wek; Amber L Mosley; Yunlong Liu; Alexander G Robling; Nickolay Brustovetsky; James Hamilton; Kylie Jacobs; Deepak Vashishth; Keith R Stayrook; Matthew R Allen; Joseph M Wallace; Joseph P Bidwell Journal: Am J Physiol Endocrinol Metab Date: 2019-01-15 Impact factor: 4.310